News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical, Co. Ltd., and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease).
Otsuka Pharmaceutical Development & Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd. announce topline results of the phase 3 clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease (Trial 17-AVP-786-305; NCT03393520).
A new survey reveals two-in-three family caregivers feel undervalued by society. The survey is a part of larger corporate caregiver commitment by Otsuka to advocate for visibility and support of family caregivers everywhere. The program was announced in November at the start of National Family Caregivers and Alzheimer’s Awareness Month.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck Pharmaceuticals LLC announce that treatment with REXULTI® (brexpiprazole) resulted in statistically significant and clinically meaningful improvements in adult patients with agitation associated with dementia due to Alzheimer’s disease, according to the complete results of the placebo-controlled pivotal phase 3 Study 213 (NCT03548584), published today in JAMA Neurology.